| --- | --- | |-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | | A Soluble LAG-3 Protein (Eftilagimod Alpha) with an Anti-PD-1 Antibody (Pembrolizumab): Results of a Phase II Study in NSCLC Frédéric Triebel MD, PhD Non-Small Cell Cancer Drug Development Summit | | | Boston, September 22 nd 2022 | Notice: Forward Looking Statements 2 T ...